SOURCE: Medpace


January 18, 2010 02:00 ET

Medpace, Inc. Continues Their European Expansion With the Acquisition of Medical Consulting Dr. Schlichtiger GmbH, a European CRO With Key Expertise in Drug Development and Special Focus on Regulatory Consulting and Drug Safety

CINCINNATI, OH--(Marketwire - January 18, 2010) - Medpace, a privately held, global, full-service clinical research organization, is pleased to announce that it has acquired Medical Consulting Dr. Schlichtiger GmbH, a European CRO with extensive drug development expertise providing customized regulatory and pharmacovigilance services to pharmaceutical, biotechnology and nutritional companies of all sizes based in Munich, Germany.

Medical Consulting will add strategic expertise to Medpace in terms of providing centralized European hubs for regulatory submissions and approvals as well as drug safety management and reporting. Medical Consulting is led by Dr. med. Ursula Schlichtiger, General Manager, and a research professional with extensive experience in clinical development, regulatory affairs, and pharmacovigilance. Medical Consulting has been working throughout Europe since 1989.

"I am pleased to have Dr. Schlichtiger join the Medpace team to support our growing presence in the European drug development market as Managing Director and Senior Director of Medical and Regulatory Affairs, Europe," said Dr. August Troendle, President and CEO, Medpace. "Dr. Schlichtiger has built a reputation in Europe as a distinguished professional having founded Medical Consulting in 1989 and building the company into an organization widely recognized for their successful interaction with European governmental agencies."

The integration of Medical Consulting Dr. Schlichtiger GmbH will begin immediately with the intent of completion by mid 2010. The leaders at Medical Consulting will continue in their roles as our businesses integrate for the significant benefit of our clients.


Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009 CenterWatch Site Survey.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With 900+ employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and central image management and reading from Imagepace.

Visit the Medpace website at


Founded in 1989, Medical Consulting GmbH operates as a privately held shareholder company headquartered in Munich, Germany. Medical Consulting offers an entire range of services in drug development supporting registration on a German and European Union level. Medical Consulting's long-lasting experience with all aspects of clinical research and drug registration has prepared them for meeting international regulatory authorities´ requirements pertaining to quality (CMC), preclinical, and clinical studies.

Visit the Medical Consulting Dr. Schlichtiger GmbH website at

Contact Information